Search results for "Hemotherapy"

showing 10 items of 1882 documents

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine…

2018

Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according…

0301 basic medicinemedicine.medical_specialtyArticle Subjectmedicine.medical_treatmentGastroenterologyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineNeutrophil to lymphocyte ratiolcsh:RC799-869ChemotherapyHepatologyProportional hazards modelbusiness.industryGastroenterologymedicine.diseasePrimary tumorGemcitabine030104 developmental biology030220 oncology & carcinogenesisPropensity score matchinglcsh:Diseases of the digestive system. Gastroenterologybusinessmedicine.drugResearch ArticleGastroenterology Research and Practice
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Breast cancer in pregnant patients: A review of the literature

2018

Breast cancer diagnosed during pregnancy is a rare occurrence at present; however, in recent years a trend towards delayed childbirth is generating an increase in its incidence. This situation requires a multidisciplinary approach involving obstetricians, oncologists and surgeons. In this review we analyse diagnostic methods, different possible treatments and long-term patient prognosis. We conducted a search for articles published in PubMed, or in abstract form from the San Antonio Breast Cancer Symposium (SABCS), the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO) annual meeting, using the search terms: "Breast cancer and pregnancy". Brea…

0301 basic medicinemedicine.medical_specialtyDiagnostic methodsmedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsAggressive disease03 medical and health sciences0302 clinical medicineBreast cancerPregnancymedicineHumansChildbirthMastectomyPatient Care TeamClinical OncologyPregnancyChemotherapyObstetricsbusiness.industryIncidence (epidemiology)Obstetrics and GynecologyPrognosismedicine.disease030104 developmental biologyReproductive Medicine030220 oncology & carcinogenesisFemalebusinessPregnancy Complications NeoplasticEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Stefania Candria 1 , Antonio Galvano 4 , Rosa Manetta 5 , Aldo Victor Giordano 5 , Sergio Carducci 5 , Alessandra Di Sibio 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 and on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, Univers…

0301 basic medicinemedicine.medical_specialtyFOLFIRINOXPhase II studyPhases of clinical research03 medical and health sciences0302 clinical medicineFIr/FOxFIr/FOx; First-line; Metastatic pancreatic ductal adenocarcinoma; Phase II study; Triplet chemotherapyInternal medicinemedicineMucositisPerformance statusbusiness.industryFirst-linemedicine.diseaseGemcitabineOxaliplatinIrinotecan030104 developmental biologyMetastatic pancreatic ductal adenocarcinomaOncology030220 oncology & carcinogenesisLiver functionTriplet chemotherapybusinessResearch Papermedicine.drug
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?

2020

Objective: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of systematic lymphadenectomy in patients with eEOC. Methods: Multi-center retrospective cohort study, comparing women with apparent eEOC who underwent comprehensive bilateral pelvic and para-aortic lymphadenectomy (defined as ≥20 lymph nodes) versus patients receiving no lymphadenectomy or lymph node sampling, from 05/1985 to 12/2016. Patients with bulky nodes at CT-scan and those without complete intra-peritoneal surgical staging were excluded. Only …

0301 basic medicinemedicine.medical_specialtyPrognosimedicine.medical_treatmentEarly-stageLymph node samplingCarcinoma Ovarian EpithelialDisease-Free SurvivalPelvisLymph node samplingCohort StudiesSurgical staging03 medical and health sciences0302 clinical medicineOvarian cancerMedicineHumansEpithelial ovarian cancerStage (cooking)early-stage; lymph node sampling; lymphadenectomy; ovarian cancer; prognosis; surgical stagingNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyRetrospective cohort studyLymphadenectomyMiddle Agedmedicine.diseaseSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIA030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionLymphadenectomyFemaleLymphRadiologyLymph NodesprognosisbusinessOvarian cancer
researchProduct

Dietary restriction: could it be considered as speed bump on tumor progression road?

2016

Dietary restrictions, including fasting (or long-term starvation), calorie restriction (CR), and short-term starvation (STS), are considered a strong rationale that may protect against various diseases, including age-related diseases and cancer. Among dietary approaches, STS, in which food is not consumed during designed fasting periods but is typically not restricted during designated feeding periods, seems to be more suitable, because other dietary regimens involving prolonged fasting periods could worsen the health conditions of cancer patients, being they already naturally prone to weight loss. Until now, the limited amount of available data does not point to a single gene, pathway, or …

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaCalorie restrictionCancer cellBiologyBioinformaticsCellular stress response03 medical and health sciencesWeight lossNeoplasmsCellular stress responseInternal medicinemedicineAnimalsHumansChemotherapyShort-term starvationSettore MED/49 - Scienze Tecniche Dietetiche ApplicateCaloric RestrictionStarvationCancerCancer cells; Cellular stress response; Chemotherapy; Diet; Fasting; Short-term starvationFastingGeneral Medicinemedicine.diseaseDietSettore MED/18 - Chirurgia Generale030104 developmental biologyEndocrinologyTumor progressionCancer cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioSignal transductionmedicine.symptomTumor Biology
researchProduct

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric canc…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Antonio Galvano 4 , Antonella Dal Mas 5 , Stefano Guadagni 6, 2 , Giuseppe Calvisi 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 , on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy 5 Pathology, S. Salva…

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaDocetaxelNeutropeniametastatic gastric cancerAnd oxaliplatin03 medical and health sciences0302 clinical medicinedocetaxel 5-fluorouracil and oxaliplatinInternal medicinemedicineMucositisdose-finding study5-fluorouracil5-fluorouracil; And oxaliplatin; Docetaxel; Dose-finding study; FD/FOx intensive regimen; First-line triplet chemotherapy; Metastatic gastric cancer; OncologyHypoalbuminemiabusiness.industrymedicine.diseaseOxaliplatinRegimen030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisfirst-line triplet chemotherapyCohortFD/FOx intensive regimenbusinessmedicine.drugResearch PaperOncotarget
researchProduct